New drug BL-M14D1 targets tough cancers in early human trial
NCT ID NCT07080242
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delivering a chemotherapy agent directly to them. The main goals are to check the drug's safety and find the right dose, while also looking for early signs that it might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clearview Cancer Institute
NOT_YET_RECRUITINGHuntsville, Alabama, 35805, United States
Contact
-
Emory Winship
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
-
John Theurer Cancer Center-Hackensack
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University
RECRUITINGColumbus, Ohio, 43201, United States
Contact
-
Prisma Health Cancer Institute
RECRUITINGGreenville, South Carolina, 29605, United States
Contact
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Dallas- Fort Worth
RECRUITINGDallas, Texas, 76104, United States
Contact
-
START- San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
UCLA
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
NOT_YET_RECRUITINGSan Francisco, California, 94158, United States
Contact
-
University of Colorado - Anschutz Cancer Pavilion
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact
-
University of Washington/Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M14D1 (a drug that targets a protein called DLL3 on cancer cells and delivers a chemotherapy payload)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 120 participants, so the drug may turn out to be unsafe or not effective. Side effects from the chemotherapy payload could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.